Rollins Inc. Common Stock vs Sana Biotechnology Inc — how do they compare? Rollins Inc. Common Stock trades at $32.61 (market cap $15.47B), while Sana Biotechnology Inc trades at $2.34 (market cap $719.96M). The key difference: Rollins Inc. Common Stock is far larger — about 21.5× Sana Biotechnology Inc's market cap, and Rollins Inc. Common Stock pays a 2.27% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rollins Inc. Common Stock for 0 Days and Sana Biotechnology Inc for 24 Days on average.
| ROL | SANA | |
|---|---|---|
Market Cap | $15.47B | $719.96M |
Volume | 6,712,154 | 4,901,517 |
Sector | Industrials | Health |
52-Week High | $65.60 | $5.92 |
52-Week Low | $29.69 | $2.33 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $16.48B | $633.21M |
Dividend Yield | 2.27% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SANA Biotechnology trades at $2.41, down 8.02% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company shows no revenue with substantial losses (-$244.17M net income in 2025) and negative cash flow, though analyst consensus remains strongly positive with 82% buy ratings. Recent investor conference presentations indicate active business development efforts.
The stock presents high-risk speculative potential with strong Wall Street support but faces fundamental challenges including no revenue generation and significant cash burn. Investment opportunity hinges on successful clinical developments, while risks include continued operational losses and potential dilution from financing activities.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Rollins Inc. provides pest control services to residential and commercial customers through its family of brands, including Orkin, across dozens of countries.
Read more on ROL →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →